Exagen
XGN
Market cap $156M

7.12 USD

+0.14

2.01%

At close Jun 13, 4:00 PM EDT

After hours

7.22

+0.10

1.40%

1 day

2.01%

5 days

-1.52%

1 month

26.47%

3 months

112.54%

6 months

23.18%

Year to date

130.42%

1 year

259.60%

5 years

-48.37%

10 years

-61.68%

About: Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

Employees: 209

Healthcare Diagnostics & Research

0

Funds holding %

of 7,296 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

0.19% more ownership

Funds ownership: 34.65% [Q4 2024] → 34.84% (+0.19%) [Q1 2025]

0% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 10

7% less funds holding

Funds holding: 41 [Q4 2024] → 38 (-3) [Q1 2025]

11% less capital invested

Capital invested by funds: $25.1M [Q4 2024] → $22.4M (-$2.66M) [Q1 2025]

43% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 7

73% less call options, than puts

Call options by funds: $18K | Put options by funds: $66K

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$7

2%

downside

Avg. target

$7.50

5%

upside

High target

$8

12%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

Cantor Fitzgerald Ross Osborn	2%downside $7	Overweight Maintained	15 May 2025
Canaccord Genuity Kyle Mikson	12%upside $8	Buy Maintained	13 May 2025

See Analyst Rankings

Financial journalist opinion

Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares

CARLSBAD, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has completed the sale of an additional 502,500 shares of its common stock at a public offering price of $5.25 per share on May 8, 2025, pursuant to the full exercise of the option granted by Exagen to the underwriter in connection with its previously announced public offering of 3,350,000 shares of common stock, which closed on May 9, 2025.

Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares

Exagen Inc. Prices Public Offering of Common Stock

CARLSBAD, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the pricing of its previously announced underwritten public offering of 3,350,000 shares of its common stock at a public offering price of $5.25 per share.

Exagen Inc. Prices Public Offering of Common Stock

Exagen Inc. Announces Proposed Public Offering of Common Stock

CARLSBAD, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has commenced an underwritten public offering of shares of its common stock.

Exagen Inc. Announces Proposed Public Offering of Common Stock

Exagen Inc. (XGN) Q1 2025 Earnings Call Transcript

Exagen Inc. (NASDAQ:XGN ) Q1 2025 Earnings Conference Call May 5, 2025 8:30 AM ET Company Participants Ryan Douglas - Investor Relations John Aballi - President & Chief Executive Officer Jeff Black - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Genuity Ross Osborn - Cantor Fitzgerald Mark Massaro - BTIG Andrew Brackmann - William Blair Paul Knight - KeyBanc Operator Greetings, and welcome to Exagen Inc. First Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

Exagen Inc. (XGN) Q1 2025 Earnings Call Transcript

Zacks Investment Research

Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates

Exagen Inc. (XGN) came out with a quarterly loss of $0.20 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.19 per share a year ago.

Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates

Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume

CARLSBAD, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2025, and recent corporate updates.

Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume

Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors

$25 Million Funded at Close to Refinance Existing Debt and Extend Maturity Additional Borrowing Capacity Provides Minimally Dilutive Growth Capital CARLSBAD, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced it has entered into an agreement with Perceptive Advisors LLC for a term loan credit facility of up to $75 million, with $25 million funded at closing to retire an existing debt facility and strengthen the balance sheet.

Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors

Exagen: Buy An Undervalued Diagnostics Developer That Is On The Path To Profitability

We initiate coverage on Exagen with a Buy rating, citing a promising turnaround with growing diagnostics, improved margins, and new biomarker tests for lupus and RA. Despite a rocky history, Exagen's recent momentum, modest valuation, and potential upside from new products make it an attractive long-term speculative buy. Financially, Exagen reported $55.6 million in 2024 revenue, improved margins, and expects positive adjusted EBITDA by Q4 2025, supported by new product launches.

Exagen: Buy An Undervalued Diagnostics Developer That Is On The Path To Profitability

Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025

CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2025, before the market opens on Monday, May 5, 2025. John Aballi, Exagen's President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company's results at 8:30 a.m. ET (5:30 a.m. PT).

Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025

Exagen Inc. (XGN) Q4 2024 Earnings Call Transcript

Exagen Inc. (NASDAQ:XGN ) Q4 2024 Results Conference Call March 11, 2025 8:30 AM ET Company Participants Ryan Douglas - Investor Relations John Aballi - President & Chief Executive Officer Jeff Black - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Genuity Ross Osborn - Cantor Fitzgerald Mark Massaro - BTIG Dan Brennan - TD Cowen Andrew Brackmann - William Blair Matthew Parisi - KeyBanc Operator Greetings, and welcome to Exagen Inc. Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Exagen Inc. (XGN) Q4 2024 Earnings Call Transcript

See News Rankings

Charts implemented using Lightweight Charts™